A highly water-soluble bromhexine hydrochloride inclusion compound and its preparation method and application
By using zinc acetate and β-cyclodextrin in bromhexine hydrochloride to generate nanocapsules, its water solubility is improved, the problem of low solubility of bromhexine hydrochloride is solved, and efficient drug administration and stable packaging are achieved. Compounds meet the effects of large-scale breeding and therapeutics.
Patent Information
- Application Number
- CN202410343448.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-25
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-03-25
AI Technical Summary
The solubility of bromhexine hydrochloride in water is extremely low, and it is difficult to meet the drug delivery needs of large-scale aquaculture. Conventional methods in the prior art have problems of stability risks and high costs.
Nanocapoles are generated by reacting zinc acetate and β-cyclodextrin in sodium polyphosphate solution and mixed with bromhexine hydrochloride. The water solubility is improved through inclusion technology, and the ratio and reaction of zinc acetate and β-cyclodextrin are controlled. conditions to achieve efficient integration.
It significantly improves the water solubility of bromhexine hydrochloride, solves the problem of insufficient drug administration concentration, has good stability in the prepared inclusion compound, meets the needs of large-scale breeding, and shows high bioavailability and therapeutic effects in livestock and poultry. .
Smart Images

Figure CN118178680B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of veterinary drugs and relates to a highly water-soluble bromhexine hydrochloride inclusion compound and a preparation method and application thereof. Background Art
[0002] In 1963, Keck first proposed the structural formula of bromhexine hydrochloride (BRH) based on the structure of styracine, and Boehringer Ingelheim of Germany conducted original research and development. In 1966, Boehringer Ingelheim launched tablets in Japan, followed by new dosage forms such as injections and fine granules. Boehringer Ingelheim's bromhexine hydrochloride injection is also available in Spain, France, Germany, Italy and other countries. Bromhexine hydrochloride, also known as bromhexamine hydrochloride, was first included in the 1977 edition of the "Chinese Pharmacopoeia". Its chemical name is N-methyl-N-cyclohexyl-2-amino-3,5-dibromobenzylamine hydrochloride, and its molecular formula is C 14 H 20 Br2N2·HCl, molecular weight is 412.60. This product is an odorless white or off-white crystalline powder, melting point is 240-244℃, pH value of bromhexine hydrochloride is 3-5, weakly acidic. Its disadvantage is that its solubility in water is extremely low, and it is difficult to administer the drug in concentrated drinking water, especially it cannot meet the dosing method of dosing in large-scale breeding.
[0003] Patent CN111789817A discloses bromhexine hydrochloride soluble powder for livestock and poultry and its preparation method. The invention adopts conventional organic acids (citric acid and malic acid) to improve the water solubility of bromhexine hydrochloride through a crushing and mixing process. Although the water solubility can reach up to 50 ppm (2% content, water solubility 0.5g to 200 mL water), it still cannot reach the minimum solubility of 1980 ppm for large-scale breeding dosing (the clinical dosage of veterinary drinking water administration is a 24h dose, concentrated 4h drinking water administration is concentrated 6 times, and the dosing device is concentrated 50 times, which is a total of 300 times the clinical dosage; the clinical dosage of bromhexine hydrochloride preparation is 6.6 ppm), and bromhexine hydrochloride is an acid salt, and excessive addition of organic acid is likely to destroy the stability of bromhexine hydrochloride. CN112618493A discloses a veterinary bromhexine hydrochloride soluble powder, preparation method and application. This invention also simply mixes powder and adds citric acid to help dissolution. The citric acid content is as high as 10-20%, which is easy to destroy the stability of the main drug. High-content citric acid is easy to store and agglomerate after crushing, and the specific water solubility is not shown in the invention content. CN114224844A discloses a bromhexine hydrochloride soluble powder and its preparation method and application. This invention also uses citric acid to help dissolution. The difference from other patents is that the conventional chelating agent EDTA-2Na is added. The maximum solubility in this embodiment can reach 1000 ppm (2.5% content, 40 g to 1L water), which also fails to meet the water solubility requirements of clinical dosing devices, and there is an instability risk under high acidity in the prescription. CN114831942A discloses a veterinary bromhexine hydrochloride soluble powder and preparation method. This invention also uses anhydrous citric acid to improve water solubility. Unlike the above-mentioned other inventions, this invention coats the raw materials to improve drug stability. However, there are some incomprehensible aspects of this method. First, powder coating is unreasonable (only granules and tablets can be coated). In addition, even if the coating is successful, the water solubility of the main drug will drop significantly after coating, and the particle size will become larger, which is inconsistent with the soluble powder dosage form with a particle size of at least 80 mesh.
[0004] Most of the current breeding entities are large-scale farms, and dosing with a dosing device has become the mainstream trend. If the problem of high water solubility of bromhexine hydrochloride is not solved, then the drug has no practical significance in veterinary clinical practice. Therefore, how to improve the high water solubility of bromhexine hydrochloride preparations needs further in-depth research. In order to solve the defect of low water solubility of bromhexine hydrochloride, the drug stability can be improved by inclusion method. However, conventional β-cyclodextrin has low solubility in water, and only 1.8g of β-cyclodextrin is dissolved in 100 mL of water at room temperature. Other highly water-soluble hydroxypropyl β-cyclodextrin, methyl β-cyclodextrin, etc. are expensive and are not suitable for veterinary drug research and development. In addition, the molecular weight of bromhexine hydrochloride has exceeded 300, and the cavity of a simple cyclodextrin cannot fully enclose the bromhexine hydrochloride molecule. Summary of the invention
[0005] In view of the problems and shortcomings in the prior art, the object of the present invention is to provide a highly water-soluble bromhexine hydrochloride inclusion compound and a preparation method and application thereof.
[0006] To achieve the purpose of the invention, the technical solution adopted by the present invention is as follows:
[0007] The first aspect of the present invention provides a method for preparing a bromhexine hydrochloride inclusion compound, comprising the following steps:
[0008] (1) adding zinc acetate and β-cyclodextrin to a sodium polyphosphate solution for reaction, and treating the reaction solution after the reaction is completed to obtain β-cyclodextrin nanocapsules;
[0009] (2) Adding bromhexine hydrochloride to an aqueous solution of β-cyclodextrin nanocapsules to obtain a mixed solution, homogenizing the mixed solution, and vacuum drying to obtain a bromhexine hydrochloride inclusion complex.
[0010] According to the preparation method of the bromhexine hydrochloride inclusion compound, preferably, the mass ratio of zinc acetate to β-cyclodextrin is (0.0003-0.0005): 1. If the amount of zinc acetate added is too much, solid zinc acetate will cause the surface of the carrier β-cyclodextrin to be fully covered or covered too much, and the synergistic effect cannot be fully reflected. If the amount of zinc acetate added is too little, the content of β-cyclodextrin nanocapsules produced by polymerization will be low.
[0011] According to the preparation method of the above-mentioned bromhexine hydrochloride inclusion compound, preferably, the mass ratio of bromhexine hydrochloride to β-cyclodextrin nanocapsules is 1:2-4. If the mass ratio of bromhexine hydrochloride to β-cyclodextrin nanocapsules>1:2-4, the inclusion carrier is too little, resulting in insufficient inclusion, and the water solubility of the product is low. If the mass ratio of bromhexine hydrochloride to β-cyclodextrin nanocapsules is <1:2-4, since bromhexine hydrochloride has been fully included, the water solubility is not significantly improved, and the prescription cost is greatly increased.
[0012] According to the above-mentioned preparation method of bromhexine hydrochloride inclusion compound, preferably, the reaction conditions in step (1) are: reaction temperature is 92-97° C., reaction time is 4-8 h, and reaction pressure is 0.02-0.04 mPa.
[0013] According to the above-mentioned method for preparing bromhexine hydrochloride inclusion compound, preferably, the mass concentration of the sodium polyphosphate solution is 1% to 3%.
[0014] According to the above-mentioned preparation method of bromhexine hydrochloride inclusion compound, preferably, the treatment process of the reaction liquid in step (1) is: removing 80% to 85% of the solvent in the reaction liquid, then adding the remaining reaction liquid into ethyl acetate, and refrigerating at -5°C to -8°C, crystallizing, filtering, and drying the filter cake to obtain β-cyclodextrin nanocapsules.
[0015] According to the above-mentioned preparation method of bromhexine hydrochloride inclusion compound, preferably, in the mixed solution in step (2), the total mass of water: bromhexine hydrochloride and β-cyclodextrin nanocapsules = (2-4): 1.
[0016] According to the above-mentioned method for preparing bromhexine hydrochloride inclusion compound, preferably, the rotation speed of the homogenization treatment in step (2) is 10000 r / min to 15000 r / min.
[0017] The second aspect of the present invention provides a bromhexine hydrochloride inclusion compound prepared by the above preparation method.
[0018] The third aspect of the present invention provides a use of the bromhexine hydrochloride inclusion compound in the preparation of a medicament for treating synovial bursitis in livestock and poultry.
[0019] The fourth aspect of the present invention provides a medicine for treating synovial bursitis in livestock and poultry, wherein the medicine for treating synovial bursitis in livestock and poultry uses the bromhexine hydrochloride inclusion complex described in the second aspect of the present invention.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] (1) The present invention utilizes polymerization reaction to transform common β-cyclodextrin, cross-linking it into spherical nanocapsules with a particle size of 60 to 100 nm, thereby increasing the cavity size and solubility of β-cyclodextrin. The prepared β-cyclodextrin nanocapsules are then mixed with bromhexine hydrochloride, and bromhexine hydrochloride inclusion complexes are prepared by inclusion technology, thereby increasing the encapsulation rate of bromhexine hydrochloride, and providing a new idea and method for preparing highly water-soluble bromhexine hydrochloride inclusion complexes in the art.
[0022] (2) The present invention can significantly improve the water solubility of bromhexine hydrochloride by controlling the dosage of the polymerization initiator zinc acetate, bromhexine hydrochloride and β-cyclodextrin nanocapsules, and solve the solubility problem of bromhexine hydrochloride. The solubility of the prepared bromhexine hydrochloride inclusion compound is greater than the minimum dosing concentration of 1980 ppm of the dosing device, and can reach a maximum of 3860 ppm, which solves the problem in the prior art that the dosing device cannot be used for dosing due to the poor water solubility of bromhexine hydrochloride, and provides an effective and feasible method for large-scale breeding.
[0023] (3) The bromhexine hydrochloride inclusion compound of the present invention has good stability, and the content of bromhexine hydrochloride is still above 95% after 6 months of acceleration. In addition, the bromhexine hydrochloride inclusion compound of the present invention can also improve the in vivo absorption of livestock and poultry. Under the same dosage, the blood drug peak concentration and bioavailability are higher than those of the prior art control group. In addition, the bromhexine hydrochloride inclusion compound prepared by the present invention not only meets the requirements of clinical dosing device administration, but also has a certain therapeutic effect on chicken synoviae Mycoplasma disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is a scanning electron microscope image of the β-cyclodextrin nanocapsules prepared by the present invention;
[0025] Figure 2 The thin layer chromatographic photograph for identifying the bromhexine hydrochloride inclusion compound of the present invention;
[0026] Figure 3 is the infrared spectrum of bromhexine hydrochloride;
[0027] Figure 4 This is the infrared spectrum of the β-cyclodextrin nanocapsules prepared by the present invention;
[0028] Figure 5 It is the infrared spectrum of the physical mixture of bromhexine hydrochloride and β-cyclodextrin nanocapsules;
[0029] Figure 6 The infrared spectrum of the bromhexine hydrochloride inclusion compound prepared by the present invention. DETAILED DESCRIPTION
[0030] The following examples are only for further explanation of the present invention. It should be noted that all technical and scientific terms used in the present invention have the same meanings as in the technical field to which the present invention belongs unless otherwise specified. The experimental methods in the following examples without specifying specific conditions are all based on conventional techniques in the technical field, or according to the conditions recommended by the manufacturer; the reagents or instruments used without specifying the manufacturer are all conventional products that can be purchased commercially.
[0031] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.
[0032] (I) Preparation of bromhexine hydrochloride inclusion complex
[0033] Example 1
[0034] A bromhexine hydrochloride inclusion compound, its preparation method is as follows:
[0035] (1) Add 9 g of zinc acetate and 30 kg of β-cyclodextrin to a sodium polyphosphate solution with a mass concentration of 1%, adjust the pH value to 8.5, and perform polymerization reaction at 95°C and 0.03 MPa for 8 hours. After the reaction, the reaction solution was evaporated by rotary evaporation to remove 80% of the solvent and then poured into vigorously stirred ethyl acetate. The mixture was then refrigerated at -6°C, crystallized, filtered, and the filter cake was dried to obtain β-cyclodextrin nanocapsules.
[0036] (2) Weigh 29 kg of β-cyclodextrin nanocapsules and add them to 87 kg of water to dissolve to obtain liquid A; weigh 14.5 kg of bromhexine hydrochloride ultrafine powder and add them to liquid A, and homogenize them with a high-speed homogenizer at 10,000 r / min to obtain liquid B. Liquid B is vacuum dried at 70°C, and the dried product is the bromhexine hydrochloride inclusion complex.
[0037] Example 2
[0038] A bromhexine hydrochloride inclusion compound, its preparation method is as follows:
[0039] (1) Add 15 g of zinc acetate and 30 kg of β-cyclodextrin to a sodium polyphosphate solution with a mass concentration of 3%, adjust the pH value to 8.5, and perform polymerization reaction at 95°C and 0.03 MPa for 8 hours. After the reaction, the reaction solution was evaporated by rotary evaporation to remove 85% of the solvent and then poured into vigorously stirred ethyl acetate. The mixture was then refrigerated at -6°C, crystallized, filtered, and the filter cake was dried to obtain β-cyclodextrin nanocapsules.
[0040] (2) Weigh 28 kg of β-cyclodextrin nanocapsules and add them to 140 kg of water to dissolve to obtain liquid A; weigh 7 kg of bromhexine hydrochloride ultrafine powder and add them to liquid A, and homogenize them with a high-speed homogenizer at 15000 r / min to obtain liquid B. Liquid B is vacuum dried at 70°C, and the dried product is the bromhexine hydrochloride inclusion complex.
[0041] Example 3
[0042] A bromhexine hydrochloride inclusion compound, its preparation method is as follows:
[0043] (1) Add 12 g of zinc acetate and 30 kg of β-cyclodextrin to a sodium polyphosphate solution with a mass concentration of 1.5%, adjust the pH value to 8.5, and perform polymerization reaction at 95°C and 0.03 MPa for 8 hours. After the reaction, the reaction solution was evaporated by rotary evaporation to remove 80% of the solvent and then poured into vigorously stirred ethyl acetate. The mixture was then refrigerated at -6°C, crystallized, filtered, and the filter cake was dried to obtain β-cyclodextrin nanocapsules.
[0044] (2) Weigh 27 kg of β-cyclodextrin nanocapsules and add them to 108 kg of water to dissolve to obtain liquid A; weigh 9 kg of bromhexine hydrochloride ultrafine powder and add them to liquid A, and homogenize them with a high-speed homogenizer at 13000 r / min to obtain liquid B. Liquid B is vacuum dried at 70°C, and the dried product is the bromhexine hydrochloride inclusion complex.
[0045] Comparative Example 1
[0046] A bromhexine hydrochloride inclusion compound, the preparation method of which is basically the same as that of Example 1, except that the amount of zinc acetate added as a polymerization initiator is changed, that is, the amount of zinc acetate added in step (1) is 6 g.
[0047] Comparative Example 2
[0048] A bromhexine hydrochloride inclusion compound, the preparation method of which is basically the same as that of Example 1, except that the amount of zinc acetate added as a polymerization initiator is changed, that is, the amount of zinc acetate added in step (1) is 18 g.
[0049] Comparative Example 3
[0050] A bromhexine hydrochloride inclusion compound, the preparation method of which is basically the same as that of Example 1, except that the mass ratio of bromhexine hydrochloride ultrafine powder to β-cyclodextrin nanocapsules is changed to 1:1, that is, the addition amount of bromhexine hydrochloride ultrafine powder in step (2) is 29 kg.
[0051] Comparative Example 4
[0052] A bromhexine hydrochloride inclusion compound, the preparation method of which is basically the same as that of Example 1, except that the mass ratio of bromhexine hydrochloride ultrafine powder to β-cyclodextrin nanocapsules is changed to 1:5, that is, the addition amount of bromhexine hydrochloride ultrafine powder in step (2) is 5.8 kg.
[0053] Comparative Example 5
[0054] The prior art CN111789817A, CN112618493A, CN114224844A and CN114831942A all adopt the method of using organic acid citric acid to dissolve bromhexine hydrochloride, and utilize unmodified β-cyclodextrin and bromhexine hydrochloride for conventional crushing and mixing, wherein the maximum amount of citric acid used is 18%.
[0055] In order to compare the present invention with the prior art, a bromhexine hydrochloride soluble powder was prepared in this comparative example. The specific preparation method was as follows: 14.5 kg of bromhexine hydrochloride, 29 kg of β-cyclodextrin and 9.5 kg of citric acid were weighed and physically crushed, and the bromhexine hydrochloride soluble powder was obtained after mixing.
[0056] 2. Structural characterization
[0057] 1. Scanning electron microscopy test of β-cyclodextrin nanocapsules
[0058] Take the β-cyclodextrin nanocapsules prepared in step (1) of Example 2, sprinkle them evenly on a metal plate with a conductive adhesive, evacuate the plate, spray gold, and observe the particle morphology under a scanning electron microscope. The results are as follows: Figure 1 shown.
[0059] from Figure 1It can be seen that the β-cyclodextrin nanocapsules are white powders, easily soluble in water, ethanol, and propylene glycol, with a melting point of 230° C. Scanning electron microscopy showed that the capsule structure was complete and the particle size distribution was 60 to 100 nm.
[0060] Thin layer chromatography identification (TCL) of bromhexine hydrochloride inclusion complex
[0061] Take 1 g of the bromhexine hydrochloride inclusion compound prepared in Example 2 in a beaker, add 50 mL of anhydrous ethanol, ultrasonicate for 10 s, centrifuge and discard the supernatant, dissolve the precipitate and add 50 mL of anhydrous ethanol, repeat the above operation twice. Collect the precipitate and dry it at 60°C. Take an appropriate amount of the dried inclusion compound (approximately equivalent to 5 mg of bromhexine hydrochloride), place it in a 2 mL centrifuge tube, add 1 mL of water to dissolve it, and obtain the test solution 2; prepare the dried physical mixture by the same method, add the mobile phase to dissolve it to obtain solution 3. Take an appropriate amount of commercially available bromhexine hydrochloride reference substance, add methanol to make a solution containing 10 mg of bromhexine hydrochloride per 1 mL, as reference substance solutions 1 and 4. According to the thin layer chromatography test, 2 μL of each of the above solutions and 1 μL of the reference solution were respectively spotted on the same silica gel GF254 plate, and chloroform-methanol-ethyl acetate-water (15:6:15:1) was used as the developing solvent. After development, it was dried and examined under ultraviolet light (GF254). The results were as follows: Figure 2 shown.
[0062] from Figure 2 It can be seen that the spot position displayed by the test solution 2 should be the same as that of the control, and the test solution 3 shows no spot, proving the formation of bromhexine hydrochloride inclusion complex.
[0063] Fourier transform infrared spectrum (FT-IR) of bromhexine hydrochloride inclusion complex
[0064] The potassium bromide tablet method was used, and the instrument was a 7600 Fourier infrared spectrometer for determination. The solid sample was placed in a constant temperature box to be fully dried, and the potassium bromide should be baked at 110°C for at least 4 h. About 1 to 1.5 mg of the sample was taken into an agate mortar, and 200 to 300 mg of dry potassium bromide was added as a dispersant. It was fully ground and placed in a tablet pressing mold with a diameter of 13 mm to spread it evenly. The pressure was applied to 10 MPa, and after maintaining the pressure for 2 minutes, the pressure was removed and the prepared test piece was taken out. The piece should be transparent visually, and the sample should be evenly distributed, without obvious granular samples. The results are as follows Figure 3 to Figure 6 As shown, Figure 3 is the infrared spectrum of bromhexine hydrochloride raw material, Figure 4 This is the infrared spectrum of β-cyclodextrin nanocapsules. Figure 5 This is the infrared spectrum of the physical mixture of bromhexine hydrochloride and β-cyclodextrin nanocapsules. Figure 6 This is the infrared spectrum of bromhexine hydrochloride inclusion complex.
[0065] from Figure 3 to Figure 6 It can be seen that the infrared spectrum of the raw material bromhexine hydrochloride will be at the wave number 3419cm -1 Up to 2945cm -1 The physical mixing process will not affect the infrared absorption of bromhexine hydrochloride, so the infrared characteristic peak of bromhexine hydrochloride will be retained. However, after inclusion of bromhexine hydrochloride, the infrared characteristic peak of 3419cm -1 Up to 2945cm -1 The infrared characteristic peaks nearby disappeared, thus proving the formation of bromhexine hydrochloride inclusion complex.
[0066] (III) Performance testing
[0067] 1. Solubility test of bromhexine hydrochloride
[0068] Take an excess of the products prepared in Examples 1 to 3 and Comparative Examples 1 to 5 (based on 200 mg of bromhexine hydrochloride) and add them to 25 mL of water, stir them in a water bath at 37±1°C for 24 h, and then filter them with a 0.22 μm filter membrane. The concentration of bromhexine hydrochloride in the samples was detected by HPLC, and the results are shown in Table 1.
[0069]
[0070] As can be seen from Table 1, the solubility of the bromhexine hydrochloride inclusion complex prepared in Examples 1 to 3 of the present invention is greater than the minimum dosing concentration of 1980 ppm for the dosing device. After changing key parameters such as polymerization initiator zinc acetate (Comparative Examples 1 and 2), the mass ratio of bromhexine hydrochloride to β-cyclodextrin nanocapsules (Comparative Example 3), the dosing concentration of the dosing device was not reached. Although Comparative Example 4 reached the dosing concentration of the dosing device, its solubility was not significantly different from that of Example 2. At the same time, the amount of β-cyclodextrin nanocapsules increased, and the prescription cost increased, which was not conducive to application and promotion. In addition, referring to the method of adding organic acid citric acid to assist dissolution in the prior art, the unmodified existing commonly used auxiliary material β-cyclodextrin was used as an auxiliary material (Comparative Example 5), and the dosing concentration of the dosing device was not reached. It can be seen that the present invention can significantly improve the water solubility of bromhexine hydrochloride by controlling the reaction conditions and the amount of raw materials, and using the method of β-cyclodextrin nanocapsule inclusion salt bromhexine, and the prepared bromhexine hydrochloride inclusion complex can be administered using a dosing device, which is convenient for large-scale breeding.
[0071] . Stability test of bromhexine hydrochloride inclusion complex
[0072] The samples prepared in Examples 1 to 3 and Comparative Examples 1 to 5 were packaged in 14-wire pure aluminum bags, and stability studies were conducted under the following investigation conditions. The results are shown in Table 2.
[0073] Investigation conditions: temperature was 40°C and relative humidity was 75%; the content of bromhexine hydrochloride was determined by HPLC, and the chromatographic conditions were octadecylsilane bonded silica gel as the filler; phosphate buffer solution (pH value adjusted to 7.5 with concentrated ammonia solution)-acetonitrile (20:80) as the mobile phase; the detection wavelength was 245 nm; the column temperature was 40°C; and the flow rate was 1.0 mL / min.
[0074]
[0075] It can be seen from the above test results that the content of bromhexine hydrochloride, an effective ingredient, in the bromhexine hydrochloride inclusion compound prepared by the present invention is still above 95% after 6 months of acceleration, while the content of bromhexine hydrochloride soluble powder (Comparative Example 5) prepared with reference to the prior art is less than 90% after 6 months of acceleration, which is only 80.3%. This shows that the bromhexine hydrochloride inclusion compound prepared by the present invention is very stable, while the prior art method of improving the water solubility of bromhexine hydrochloride by organic acid is not as stable as described in its patent. This is mainly because the optimum pH value of bromhexine hydrochloride alkali and hydrochloric acid salt formation in the synthesis process of bromhexine hydrochloride is 6.0, and too low pH will destroy the acid structure of bromhexine, so the content of bromhexine hydrochloride in Comparative Example 5 decreases significantly after acceleration. Comparative Examples 1 to 4 do not contain organic acids, and the stability is not significantly different from that of the embodiments.
[0076] . Pharmacokinetic studies
[0077] 40 yellow-feathered broilers were randomly divided into two groups, namely experimental group 1 and experimental group 2, with 20 chickens in each group (half male and half female). The dosage of bromhexine hydrochloride in both groups was 6.6 mg / L, and the administration method was oral administration. The drug used in experimental group I was the bromhexine hydrochloride inclusion compound prepared in Example 1 of the present invention, and the bromhexine hydrochloride soluble powder prepared in Comparative Example 5 of the present invention was used in experimental group II.
[0078] The two groups of experimental animals were fasted for 12 h before administration, and about 1.1 mL of blood was collected from the right subwing vein at 10 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 7 h, 10 h, 12 h, 24 h, 36 h, 48 h, 60 h, 72 h, 84 h, and 96 h after administration. After anticoagulation with sodium heparin, the blood was centrifuged at 4000 r / min for 10 min to separate the plasma samples, which were stored in a -20°C refrigerator.
[0079] Accurately measure 500 μL of plasma, add 300 μL of 0.1 g / mL ascorbic acid solution and 200 μL of 18% perchloric acid solution, vortex for 3 min, centrifuge at 12000 r / min for 15 min, filter the supernatant through a 0.22 μm handheld syringe filter, place it in an injection bottle, and perform high performance liquid chromatography to detect the content of bromhexine hydrochloride. Calculate the pharmacokinetic parameter T based on the test results max , C max 、T 1 / 2 K a and AUC 0-∞ The specific results are shown in Table 3.
[0080]
[0081] As shown in Table 3, the pharmacokinetic parameters T of the bromhexine hydrochloride inclusion compound of Example 1 of the present invention are max and T 1 / 2Ka Compared with comparative example 5, the difference is not significant, indicating that Example 1 of the present invention does not change the peak time and elimination rate of bromhexine hydrochloride in broilers. However, the pharmacokinetic parameters C of bromhexine hydrochloride in Example 1 of the present invention max and AUC 0-∞ Compared with Comparative Example 5, the difference is significant, showing that under the same dosage, the peak blood drug concentration and bioavailability of Example 1 of the present invention are higher than those of the prior art control group, thereby also proving that the bromhexine hydrochloride inclusion compound of the present invention can not only improve the water solubility of bromhexine hydrochloride, but also improve the in vivo absorption of livestock and poultry, and has achieved very good results compared with the existing formulation technology.
[0082] Effect test
[0083] Test Example 1
[0084] Experimental study on the therapeutic effect of the bromhexine hydrochloride inclusion compound described in Example 1 of the present invention in the treatment of synovial bursitis in livestock and poultry.
[0085] (1) Experimental animals
[0086] The sick chickens were provided by a white-feathered broiler farm in Xinzheng City, Henan Province. The specific situation was as follows: 400 20-day-old white-feathered broilers were selected. The chickens showed swollen joints and loss of appetite, and were diagnosed as synovial bursa disease caused by mycoplasma infection by clinical veterinarians.
[0087] (2) Experimental drugs
[0088] Commercially available doxycycline hydrochloride soluble powder (Henan Muxiang Animal Pharmaceutical Co., Ltd., batch number: 230507);
[0089] The bromhexine hydrochloride inclusion compound prepared in Example 1 of the present invention.
[0090] (3) Trial groups and administration methods
[0091] The chickens were randomly divided into 4 groups, namely experimental group I, II, III and experimental group IV (blank control group), with 100 chickens in each group. The 4 groups of chickens were raised in the same environment. The 4 groups of chickens were given medication through drinking water with a dosing device for 4 hours for 5 consecutive days. After the treatment, the mental state and appetite of the chickens were observed. The specific experimental grouping and medication method are shown in Table 4.
[0092]
[0093] (4) Efficacy determination and result analysis
[0094] The criteria for judging cure are: after drug administration through drinking water during the trial period, clinical symptoms are significantly improved, the patient can walk normally, has a good mental state and appetite, and the clinical symptom score is reduced by more than 80%.
[0095] The effective judgment criteria are: after drug administration through drinking water during the trial, clinical symptoms are significantly improved, normal walking can be achieved, and the clinical symptom score is reduced by 30% to 80%.
[0096] Ineffective: After drug administration through drinking water during the trial, clinical symptoms did not improve significantly, and the clinical symptom score decreased by less than 30%; chickens that died during the trial were counted as ineffective.
[0097] The clinical symptom scoring criteria are shown in Table 5:
[0098]
[0099] The improvement results of each group of chickens are shown in Table 6, where the effective rate = number of effective chickens / number of chickens in the group × 100%, the cure rate = number of cured chickens / number of chickens in the group × 100%, and the ineffective rate = number of ineffective chickens / number of chickens in the group × 100%.
[0100]
[0101] As shown in Table 6, the bromhexine hydrochloride inclusion compound prepared by the present invention and the commercially available doxycycline hydrochloride soluble powder both have certain therapeutic effects on mycoplasma synoviae disease in white-feathered broilers. When the two are administered in combination, the effective rate and cure rate are the highest, and the mortality rate is the lowest. It can be seen that the bromhexine hydrochloride inclusion compound prepared by the present invention not only meets the requirements of clinical dosing device administration, but also has the best clinical therapeutic effect on mycoplasma synoviae disease in white-feathered broilers when used in combination with the commercially available respiratory antibacterial drug doxycycline hydrochloride soluble powder.
[0102] Test Example 2
[0103] Experimental study on the therapeutic effect of the bromhexine hydrochloride inclusion compound described in Example 2 of the present invention in the treatment of synovial bursitis in livestock and poultry.
[0104] (1) Experimental animals
[0105] The sick chickens were provided by a yellow-feathered broiler farm in Heze City, Shandong Province. The specific situation was as follows: 400 35-day-old yellow-feathered broilers were selected. The chickens had swollen joints and effusion, and were diagnosed with synoviae Mycoplasma disease by clinical veterinarians.
[0106] (2) Experimental drugs
[0107] Commercially available tylvalosin tartrate soluble powder (Henan Muxiang Animal Pharmaceutical Co., Ltd., batch number: 230702);
[0108] The bromhexine hydrochloride inclusion compound prepared in Example 2 of the present invention.
[0109] (3) Trial groups and administration methods
[0110] The chickens were randomly divided into 4 groups, namely experimental group I, II, III and experimental group IV (blank control group), with 100 chickens in each group. The 4 groups of chickens were raised in the same environment and medicated with drinking water for 4 hours using a dosing device for 5 consecutive days. After the treatment, the mental state and appetite of the chickens were observed. The specific experimental grouping and medication method are shown in Table 7.
[0111]
[0112] (4) Efficacy assessment and results
[0113] The scoring standard for efficacy determination is the same as that of Experimental Example 1. The specific treatment results are shown in Table 8.
[0114]
[0115] From the results in Table 8, it can be seen that the bromhexine hydrochloride inclusion compound and the tylvalosin tartrate soluble powder have a certain preventive and therapeutic effect on the Mycoplasma synoviae disease in yellow-feathered broilers. When the two are administered in combination, the effective rate and cure rate are the highest, and the mortality rate is the lowest. It can be seen that the bromhexine hydrochloride inclusion compound prepared by the present invention not only meets the requirements of clinical dosing device administration, but also has the best clinical effect on the Mycoplasma synoviae disease in yellow-feathered broilers when used in combination with the commercially available tylvalosin tartrate soluble powder.
[0116] The above embodiments are specific implementation methods of the present invention, but the implementation methods of the present invention are not limited to the above embodiments. Any other combination, change, modification, substitution and simplification that does not exceed the design concept of the present invention shall fall within the protection scope of the present invention.
Claims
1. A method for preparing a bromhexine hydrochloride inclusion compound, characterized in that, The following steps are involved: (1) adding zinc acetate and β-cyclodextrin to a sodium polyphosphate solution for reaction, and treating the reaction solution after the reaction is completed to obtain β-cyclodextrin nanocapsules; (2) adding bromhexine hydrochloride to an aqueous solution of β-cyclodextrin nanocapsules to obtain a mixed solution, homogenizing the mixed solution, and vacuum drying the mixed solution to obtain a bromhexine hydrochloride inclusion complex; The mass ratio of zinc acetate to beta-cyclodextrin is (0.0003-0.0005):1; The mass ratio of bromhexine hydrochloride to beta-cyclodextrin nanocapsules is 1:(2-4).
2. The preparation method of bromhexine hydrochloride inclusion compound according to claim 1, wherein The reaction conditions in step (1) are: reaction temperature of 92-97° C., reaction time of 4-8 h, and reaction pressure of 0.02-0.04 MPa.
3. the preparation method of bromhexine hydrochloride inclusion compound according to claim 2, is characterized in that, The mass concentration of the sodium polyphosphate solution is 1% to 3%.
4. The preparation method of bromhexine hydrochloride inclusion compound according to claim 3, wherein In terms of mass, in the mixed solution of step (2), the total mass of water: bromhexine hydrochloride and β-cyclodextrin nanocapsules is (2-4):
1.
5. A bromhexine hydrochloride inclusion compound prepared by the preparation method according to any one of claims 1 to 4.
6. Use of the bromhexine hydrochloride inclusion compound according to claim 5 in the preparation of a medicament for treating chicken synoviae mycoplasma disease.
7. A drug for treating chicken synoviae mycoplasma disease, characterized in that: The medicine for treating chicken synoviae mycoplasma disease uses the bromhexine hydrochloride inclusion compound as described in claim 5.
